- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | OS Therapies Bone Cancer Trial Data Strengthens FDA Case | 3 | Benzinga.com | ||
| 15.01. | OS Therapies: OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 126 | Newsfile | Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (Pre-specified pathway analysis strategy developed as... ► Artikel lesen | |
| 14.01. | OS Therapies: OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | 360 | Newsfile | OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first... ► Artikel lesen | |
| 12.01. | OS Therapies: OS Therapies Enters into Warrant Inducement Agreements | 167 | Newsfile | $7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet proceeds to fund OST-HER2 regulatory approval... ► Artikel lesen | |
| 12.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | OS Therapies provides first half 2026 corporate outlook | 3 | Seeking Alpha | ||
| 05.01. | OS Therapies: OS Therapies Provides First Half 2026 Corporate Outlook | 380 | Newsfile | Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary... ► Artikel lesen | |
| 09.12.25 | OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 363 | Newsfile | Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 05.12.25 | OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility | 478 | Newsfile | U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency... ► Artikel lesen | |
| 25.11.25 | OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization | 350 | Newsfile | New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today... ► Artikel lesen | |
| 20.11.25 | OS Therapies to spin off OS Animal Health into a standalone public company | 5 | Seeking Alpha | ||
| 20.11.25 | OS Therapies plans to spin off animal health unit as public company | 5 | Investing.com | ||
| 20.11.25 | OS Therapies to Spinoff OS Animal Health into Standalone Public Company | 360 | Newsfile |
Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me: Cancer Pioneers' film... ► Artikel lesen | |
| 17.11.25 | OS Therapies: Aktie fällt nach höherem Quartalsverlust im Zuge von Zulassungsvorbereitungen | 16 | Investing.com Deutsch | ||
| 17.11.25 | OS Therapies GAAP EPS of -$0.21 misses by $0.08 | 5 | Seeking Alpha | ||
| 17.11.25 | OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update | 355 | Newsfile | Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent... ► Artikel lesen | |
| 31.10.25 | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.10.25 | OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 381 | Newsfile | New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 17.10.25 | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 503 | Newsfile | Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation &... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 42,000 | -0,47 % | Citizens senkt Kursziel für CRISPR Therapeutics auf 80 US-Dollar, bleibt aber optimistisch | ||
| IMMUNIC | 0,528 | +0,96 % | EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones | Issuer: Immunic AG
/ Key word(s): Miscellaneous/Conference
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
07.01.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,010 | -0,98 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 4,013 | +1,31 % | ANAVEX LIFE SCIENCES CORP: Jetzt wird's ernst am Markt! | ||
| ARCTURUS THERAPEUTICS | 7,490 | -1,19 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,550 | -0,66 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,990 | +1,53 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio (pegunigalsidase alfa) - in the EU | Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March... ► Artikel lesen | |
| GEOVAX LABS | 2,760 | -2,82 % | EQS-News: GeoVax Labs, Inc.: GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement | GeoVax, Inc. / Key word(s): Financial
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
08.01.2026 / 15:03 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| SCILEX | 8,520 | +0,06 % | Scilex invests $20 million in medical tech firm Quantum Scan | ||
| INVIVYD | 1,745 | -6,18 % | Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 | Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people... ► Artikel lesen | |
| MEIRAGTX | 6,350 | 0,00 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,775 | -1,21 % | Tenaya Therapeutics, Inc. - 8-K, Current Report | ||
| UNICYCIVE THERAPEUTICS | 5,965 | -10,57 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission | DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE... ► Artikel lesen | |
| QIAGEN | 44,620 | +0,64 % | QIAGEN: Wochengewinner im DAX - Analyse der KW 4 | ||
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 |
OS THERAPIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,015 (-1,08 %) liegt der Kurs bei 1,375 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.